|
|
 |
|
Viewing report
|
|
|
|
The Diabetes Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
Business Insights, Jan 2005
Inject new strategies into your diabetes product pipeline and maximize product potential with a review of new and emerging drug classes.
Keep abreast of competitive developments in the diabetes market with a strategic analysis of all major drugs, including newly approved therapies.
Discover how the race for the first non-invasive insulin product: inhalers, sprays, pills and patches is unfolding, with the latest developments unveiled in this report.
This unique report offering provides an analysis of changing market conditions and strategic future outlook. A 'must-have' source of pharmaceutical intelligence with powerful analysis that will put you ahead of your competitors.
Refresh your diabetes strategy with new analysis
This new report analyzes diabetes market dynamics and provides a country-by-country brand analysis, enabling you to assess product success or failure within US and European geographical markets. This report focuses on key anti-diabetic drugs and reviews the growth strategies of leading players. Upcoming revolutionary products in development are also investigated, highlighting those expected to drive market growth and transform treatment options for diabetic patients.
Ensure you maximize the opportunities presented by the epidemic of patients affected by type 2 diabetes, drive product development and exploit new and existing revenue streams in this rapidly growing market.
This report provides:
- Value and growth breakdowns of the insulin market and all sub-sections of OADs from 2002 - 2003. The report also includes a sales breakdown by country, highlighting differences in usage of TZDs in the US and European sectors.
- Strategic analysis of all major diabetes drugs, such as Actos, Avandia, Humalog, NovoLin and Lantus, as well as newly approved therapies Levemir and Apidra.
- An examination of the key trends which are currently affecting the market such as the increasing use of insulin and combination therapies amongst type 2 diabetics.
- An in-depth analysis of the future growth drivers in the market, such as development of non-invasive insulins, PPAR agonists and GLP-1 agonists.
- Company analysis and market shares of insulin and OAD markets in the US and Europe, including Eli Lilly, Novo Nordisk, Sanofi-Aventis, Takeda, GSK and BMS.
- Comprehensive review of the major companies’ R&D portfolios.
Key findings of this new report
- Non-invasive insulins will address the key unmet need in the diabetes market. Several pills, inhalers, mouth sprays and patches are in development and this is likely to cause an increase in the number of users in the type 2 patient population currently put off by subcutaneous injections.
- Dual PPAR agonists have blockbuster potential because they can treat both diabetes and heart disease.
- Type 2 diabetes has now hit epidemic levels, and is expected to increase further over the coming years with the rise in the age demographic and the escalation in rates of obesity.
- TZDs are the highest selling products in the US diabetes market, but have had little market penetration in Europe, due to continued concern about the safety of the class following the withdrawal of Rezulin.
- The insulin market is dominated by three companies – Eli Lilly, Novo Nordisk and Sanofi-Aventis – but the OAD market is more diverse and more valuable, thus representing more opportunities for entry.
- Combining drugs into single-pill formulations has proved to be a valuable life-cycle management tool for several companies, for example GSK has combined Avandia with metformin to make Avandamet.
Actionable strategies to drive your profits forward
- Save valuable time and budget on diabetes market research with this report's expert analysis of all major diabetic drugs, using gold standard IMS Health data.
- Increase your market share by identifying where the major growth opportunities lie and exploiting the unmet needs in each market.
- Maximize your products' success by understanding the differences in US and European markets and tailoring your strategy accordingly.
- Establish the optimum position for your company in the diabetes marketplace, by identifying who your main competitors are and how they are preparing their portfolios for the future in the diabetes market.
- Drive your company's future growth prospects by examining the key trends affecting the diabetes market and discover how they are shaping the future of this market.
Customers who bought this item also bought
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
Competitor Analysis: Insulin
Market Research of Diabetes and its Treatment Medicine-Insulin in China, 2008
Pipeline Insight: Insulin Antidiabetics - Return to Injections - Alternative Delivery Methods Fall by the Wayside
Diabetes, Metabolic Syndrome and Cardiovascular Disease
Stakeholder Insight: Diabetes
Insulin Delivery Devices Market Analysis and Future Forecast
Pipeline Insight: Non-Insulin Antidiabetics - Type 2 Diabetes Unlikely To Develop Into a Switch Market
Insulin Delivery Systems Market Analysis (2007-2010)
Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015
The Diabetes Market Outlook to 2011
Pipeline Insight: Non-Insulin Antidiabetics � Incretin Mimetics � Leaders in a Diverse Pipeline
|
|
|
|
